News
06-09-2008, 06:00 PM
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing.
More... (http://www.medicalnewstoday.com/articles/109619.php)
More... (http://www.medicalnewstoday.com/articles/109619.php)